An enormous amount of research effort has been devoted to biomarker discovery and
validation. With the completion of the human genome, proteomics is now playing an …

Prostate cancer (PCa) is one of the most commonly diagnosed malignancies and among the
leading causes of cancer-related death worldwide. It is a highly heterogeneous disease …

Label-free biosensing based on metallic nanoparticles supporting localized surface
plasmon resonances (LSPR) has recently received growing interest (Anker, JN, et al. Nat …

The different prostate cancer (PCa) cell populations (bulk and cancer stem cells, CSCs)
release exosomes that contain miRNAs that could modify the local or premetastatic niche …

Prostatic hyperplasia (PH) is a common urologic disease that affects mostly elderly men. PH
can be classified as benign prostatic hyperplasia (BPH), or prostate cancer (PCa) based on …

Prostate cancer (PCa) is the most prevalent cancer with a high mortality rate. The early and
accurate detection of PCa can significantly reduce mortality and saves lives. Hence, the …

The accurate identification and stratified treatment of clinically significant early-stage
prostate cancer have been ongoing concerns since the outcomes of large international …

We here report the development of an aptamer based biosensor for the investigation of
prostate specific antigen (PSA), a biomarker found in blood for prostate cancer (PCa), using …

The transmembrane protease serine 2: v‑ets erythroblastosis virus E26 oncogene homolog
(TMPRSS2: ERG) gene fusion is common in prostate cancer, while its functional role is not …

Screening serum for the presence of prostate specific antigen (PSA) belongs to the most
common approach for the detection of prostate cancer. This review (with 156 refs.) …